Consistent with this hypothesis, dapagliflozin slowed tumor growth in mouse models of obesity-associated breast and colon cancer; however, the ability of dapagliflozin to slow tumor growth was completely abrogated by subcutaneous insulin infusion to increase plasma insulin concentrations to those measured in HFD controls. The gene discussed is INS; the disease is obesity disorder.